AIM today
$0.14-$0.01 (-3.63%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourBearish
15 minStrong Bearish
5 minExpanding
Daily trend turns up above $0.17
Key levels
Resistance$0.17
Resistance$0.15
Support$0.13
Support$0.12
Latest news & SEC filings
EarningsAIM ImmunoTech Posts Q3 2026 Results, Business Update
SEC FilingAIM ImmunoTech Inc. filed an insider trading report (Form 4)
EarningsAIM ImmunoTech posts wider quarterly loss as revenue slips
All AIM news →About AIM ImmunoTech
AIM ImmunoTech is a pharmaceutical research company headquartered in Ocala, Florida, working on treatments for tumor diseases, infections, and conditions where the body's defenses are weakened. Its lead candidate is Ampligen, a synthetic RNA being studied for pancreatic tumors, lingering fatigue after COVID-19, and antiviral applications, while Alferon N Injection is an interferon-based product. The company conducts trials, frequently pairing its drugs with other medicines, and works with hospitals and partners in the United States, Europe, and Argentina.
Based on the company's 10-K filed Mar 27, 2026.
NYSE · Healthcare
AIM ImmunoTech Inc. (AIM)
What Is the Price Target for AIM?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is AIM a Buy or Sell Right Now?
Thesis
- •Revenue growing -48.2% YoY with DECLINING trend — consistent growth.
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for AIM.
Start Free Trial →Is AIM Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B
Fair Value
$1.17
0
Moat Score
NONE
2/9
Piotroski Score
-114.0
Altman Z-Score
What Is Smart Money Doing with AIM?
Insider Signal
BUYING
4 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Equels Thomas K | director officer | Buy | 39,000 | $5K | Nov 10, 2026 |
| Equels Thomas K | director officer | Buy | 31,298 | $5K | Nov 9, 2026 |
| Equels Thomas K | director officer | Buy | 20,299 | $3K | Nov 6, 2026 |
| Equels Thomas K | director officer | Buy | 31,250 | $5K | Oct 22, 2026 |
| Equels Thomas K | director officer | Buy | 24,000 | $5K | Sep 17, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →AIM Growth Story
Revenue YoY
-48.2%
3yr Revenue CAGR
-14.5%
EPS Growth YoY
72.12%
FCF Growth YoY
N/A%
Revenue Trend
DECLINING
Dark Pool Trades for AIM
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for AIM, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:02:41 | $0.14 | 1,000 | $$143 | SELL |
| 18:58:21 | $0.14 | 8,500 | $$1K | SELL |
| 18:56:12 | $0.14 | 9,000 | $$1K | BUY |
| 18:52:41 | $0.14 | 1,000 | $$143 | SELL |
| 17:38:56 | $0.14 | 1,758 | $$250 | SELL |
5 dark pool trades shown · $$3K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for AIM ImmunoTech Inc. (AIM) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →AIM — frequently asked questions
What is AIM stock price today?
AIM ImmunoTech Inc. (AIM) is at $0.14, down 3.63% (-$0.01) at the Nov 13, 2026 close.
Why is AIM stock moving today?
Latest AIM news — Nov 13, 2026: AIM ImmunoTech Posts Q3 2026 Results, Business Update · Nov 13, 2026: AIM ImmunoTech Inc. filed an insider trading report (Form 4)
What do analysts rate AIM?
Analyst ratings for AIM: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
Did AIM beat earnings?
AIM last reported on Aug 10, 2026: EPS -$0.43 vs -$0.17 expected — a miss of 152.9%.
Does AIM pay a dividend?
AIM does not currently pay a dividend.
How much debt does AIM have?
AIM ImmunoTech Inc. reported $4M of debt and $10M of cash (Jun 30, 2026).
What are AIM support and resistance levels?
Support: $0.13, $0.12, $0.06. Resistance: $0.15, $0.17, $0.19.
What are insiders doing with AIM?
Insider activity: BUYING, 4 buys and 0 sells in the last 90 days.
What is the latest news on AIM?
Nov 13, 2026: AIM ImmunoTech Posts Q3 2026 Results, Business Update · Nov 13, 2026: AIM ImmunoTech Inc. filed an insider trading report (Form 4) · Nov 12, 2026: AIM ImmunoTech posts wider quarterly loss as revenue slips